1 / 6

Ledipasvir-sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIH SYNERGY

Phase 2. Treatment Naïve (unfavorable baseline treatment characteristics). Ledipasvir-sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIH SYNERGY. Kohli A, et al. 21 st CROI. 2014:Abstract 27LB. . Sofosbuvir-Ledipasvir +/- GS-9669 or GS-9451 in Naïve GT1 NIH SYNERGY Trial : Features.

elma
Download Presentation

Ledipasvir-sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIH SYNERGY

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2 TreatmentNaïve (unfavorable baseline treatment characteristics) Ledipasvir-sofosbuvir +/- 3rd DAA in HCV Genotype 1 NIH SYNERGY KohliA, et al. 21st CROI. 2014:Abstract 27LB.

  2. Sofosbuvir-Ledipasvir +/- GS-9669 or GS-9451 in Naïve GT1NIH SYNERGY Trial: Features Source: Kohli A, et al. 21st CROI. 2014:Abstract 27LB.

  3. Sofosbuvir-Ledipasvir +/- GS-9669 or GS-9451 in Naïve GT1NIH SYNERGY Trial: Participants Source: Kohli A, et al. 21st CROI. 2014:Abstract 27LB.

  4. Sofosbuvir-Ledipasvir +/- GS-9669 or GS-9451 in Naïve GT1NIH SYNERGY Trial: Features 0 6 12 Week Treatment NaïveAll stages fibrosis Ledipasvir + Sofosbuvir n =20 SVR12 Treatment NaïveCirrhosis excluded Ledipasvir + Sofosbuvir + GS-9669 n = 20 SVR12 Treatment NaïveCirrhosis excluded Ledipasvir + Sofosbuvir + GS-9451 n = 20 SVR12 Drug Classes/MechanismLedipasvir (investigational): NS5A inhibitorSofosbuvir: nucleotide NS5B polymerase inhibitor GS-9669 (investigational): non-nucleoside NS5B inhibitorGS-9451 (investigational): NS3/4 protease inhibitor Drug DosingLedipasvir-Sofosbuvir: 90/400 mg fixed dose combination one pill once dailyGS-9669: 500 mg once dailyGS-9451: 80 mg once daily Source: Kohli A, et al. 21st CROI. 2014:Abstract 27LB.

  5. Sofosbuvir-Ledipasvir +/- GS-9669 or GS-9451 in Naïve GT1NIH SYNERGY Trial: Features NIH SYNERGY: SVR 12 by Treatment Regimen 20/20 19/20 20/20 Source: Kohli A, et al. 21st CROI. 2014:Abstract 27LB.

  6. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related